Perspective Therapeutics (CATX) 10-Q 15 May 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Mar. 31, 2014	7-May-14
Document and Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Entity Registrant Name	'IsoRay, Inc.	'
Entity Central Index Key	'0000728387	'
Trading Symbol	'isr	'
Current Fiscal Year End Date	'--06-30	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	54,392,781

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Jun. 30, 2013
Current assets:	'	'
Cash and cash equivalents	$23,702,901	$2,899,927
Accounts receivable, net of allowance for doubtful accounts of $71,377 and $52,598, respectively	805,326	923,780
Inventory	387,020	405,571
Prepaid expenses and other current assets	212,079	214,382
Total current assets	25,107,326	4,443,660
Fixed assets, net of accumulated depreciation and amortization	1,183,067	1,684,282
Restricted cash	181,194	181,149
Inventory, non-current	469,758	469,758
Other assets, net of accumulated amortization	258,619	276,507
Total assets	27,199,964	7,055,356
Current liabilities:	'	'
Accounts payable and accrued liabilities	609,761	432,566
Accrued protocol expense	75,057	25,305
Accrued radioactive waste disposal	130,301	100,000
Accrued payroll and related taxes	87,660	127,419
Accrued vacation	117,971	107,578
Total current liabilities	1,020,750	792,868
Warrant derivative liability	678,000	104,000
Asset retirement obligation	847,351	792,242
Total liabilities	2,546,101	1,689,110
Commitments and contingencies (Note 6)	'	'
Shareholders' equity:	'	'
Preferred stock, $.001 par value; 7,001,671 shares authorized:	59	59
Common stock, $.001 par value; 192,998,329 & 193,000,000 shares authorized; 54,181,444 and 34,618,517 shares issued and outstanding	54,181	34,618
Treasury stock, at cost 13,200 shares	-8,390	-8,390
Additional paid-in capital	80,980,664	57,431,293
Accumulated deficit	-56,372,651	-52,091,334
Total shareholders' equity	24,653,863	5,366,246
Total liabilities and shareholders' equity	27,199,964	7,055,356
Series A Preferred Stock [Member]	'	'
Shareholders' equity:	'	'
Preferred stock, $.001 par value; 7,001,671 shares authorized:	'	'
Series B Preferred Stock [Member]	'	'
Shareholders' equity:	'	'
Preferred stock, $.001 par value; 7,001,671 shares authorized:	59	59
Series C Preferred Stock [Member]	'	'
Shareholders' equity:	'	'
Preferred stock, $.001 par value; 7,001,671 shares authorized:	'	'
Series D Preferred Stock [Member]	'	'
Shareholders' equity:	'	'
Preferred stock, $.001 par value; 7,001,671 shares authorized:	'	'

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Jun. 30, 2013
Accounts receivable, allowance for doubtful accounts	$71,377	$52,598
Preferred stock, par or stated value per share	$0.00	$0.00
Preferred stock, shares authorized	7,001,671	'
Common stock, par value per share	$0.00	$0.00
Common stock, shares authorized	192,998,329	193,000,000
Common stock, shares issued	54,181,444	34,618,517
Common stock, shares outstanding	54,181,444	34,618,517
Treasury stock, shares	13,200	13,200
Series A Preferred Stock [Member]	'	'
Preferred stock, par or stated value per share	$0.00	$0.00
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series B Preferred Stock [Member]	'	'
Preferred stock, par or stated value per share	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	59,065	59,065
Preferred stock, shares outstanding	59,065	59,065
Series C Preferred Stock [Member]	'	'
Preferred stock, par or stated value per share	$0.00	$0.00
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series D Preferred Stock [Member]	'	'
Preferred stock, par or stated value per share	$0.00	$0.00
Preferred stock, shares authorized	1,671	0
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Consolidated Statements of Operations [Abstract]	'	'	'	'
Product sales	$1,134,319	$1,251,478	$3,269,642	$3,283,167
Cost of product sales	1,083,413	1,065,574	3,329,950	3,276,314
Gross profit / (loss)	50,906	185,904	-60,308	6,853
Operating expenses:	'	'	'	'
Research and development expenses	153,611	155,137	470,631	445,785
Sales and marketing expenses	245,558	290,812	931,210	928,962
General and administrative expenses	640,732	564,075	1,805,732	1,678,487
Total operating expenses	1,039,901	1,010,024	3,207,573	3,053,234
Operating loss	-988,995	-824,120	-3,267,881	-3,046,381
Non-operating income (expense):	'	'	'	'
Interest income	556	83	1,391	355
Change in fair value of warrant derivative liability	-1,095,000	109,000	-1,014,000	183,000
Financing and interest expense	'	'	-827	-6
Non-operating income / (expense), net	-1,094,444	109,083	-1,013,436	183,349
Net loss	-2,083,439	-715,037	-4,281,317	-2,863,032
Preferred stock deemed dividends (Note 9)	'	'	-726,378	'
Preferred stock dividends	-2,658	-2,658	-7,974	-7,974
Net loss applicable to common shareholders	($2,086,097)	($717,695)	($5,015,669)	($2,871,006)
Basic and diluted loss per share	($0.05)	($0.02)	($0.13)	($0.08)
Weighted average shares used in computing net loss per share:	'	'	'	'
Basic and diluted	42,506,077	34,611,517	38,852,980	34,359,567

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	9 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'
Net loss	($4,281,317)	($2,863,032)
Adjustments to reconcile net loss to net cash used by operating activities:	'	'
Allowance for doubtful accounts	18,779	-32,174
Depreciation and amortization of fixed assets	517,548	563,850
Amortization of deferred financing costs and other assets	23,056	21,036
Change in fair value of warrant derivative liability	1,014,000	-183,000
Accretion of asset retirement obligation	55,109	50,383
Share-based compensation	65,217	85,369
Changes in operating assets and liabilities:	'	'
Accounts receivable, gross	99,675	67,195
Inventory	18,551	87,368
Other receivables	4,516	2,204
Prepaid expenses and other current assets	-2,213	-69,427
Accounts payable and accrued expenses	177,195	-21,525
Accrued protocol expense	49,752	27,500
Accrued radioactive waste disposal	30,301	36,000
Accrued payroll and related taxes	-39,759	-54,654
Accrued vacation	10,393	12,961
Net cash used by operating activities	-2,239,197	-2,269,946
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'
Purchases of fixed assets	-16,333	'
Additions to licenses and other assets	-5,168	-12,926
Change in restricted cash	-45	-104
Net cash used by investing activities	-21,546	-13,030
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'
Preferred dividends paid	-10,632	-10,632
Proceeds from sales of preferred stock, pursuant to underwritten offering, net	1,478,703	'
Proceeds from sales of common stock, pursuant to underwritten offering, net	1,800,589	'
Proceeds from sales of common stock, pursuant to registered direct offering, net	13,818,927	3,291,977
Proceeds from sales of common stock, pursuant to exercise of warrants, net	5,961,001	1,825
Proceeds from sales of common stock, pursuant to exercise of options	15,129	11,309
Net cash provided by financing activities	23,063,717	3,294,479
Net increase in cash and cash equivalents	20,802,974	1,011,503
Cash and cash equivalents, beginning of period	2,899,927	2,672,711
CASH AND CASH EQUIVALENTS, END OF PERIOD	23,702,901	3,684,214
Non-cash investing and financing activities:	'	'
Reclassification of derivative warrant liability to equity upon exercise	-440,000	'
Reclassification of convertible preferred stock to common stock upon conversion	($1,478,703)	'

Basis_of_Presentation

Basis of Presentation	9 Months Ended
	Mar. 31, 2014
Basis of Presentation [Abstract]	'
Basis of Presentation	'
	1	Basis of Presentation
	The accompanying consolidated financial statements are those of IsoRay, Inc., and its wholly-owned subsidiaries (IsoRay or the Company). All significant intercompany accounts and transactions have been eliminated in consolidation. Certain amounts in the prior-year financial statements have been reclassified to conform to the current year presentation.
	In the opinion of management, the accompanying unaudited interim consolidated financial statements and notes to the interim consolidated financial statements contain all adjustments, consisting of normal recurring items, necessary to present fairly, in all material respects, the financial position of IsoRay, Inc. and its wholly-owned subsidiaries.  These unaudited interim consolidated financial statements should be read in conjunction with our audited consolidated financial statements and related footnotes as set forth in the Company's annual report filed on Form 10-K for the year ended June 30, 2013, as it may be amended from time to time.
	The results of operations for the periods presented may not be indicative of those which may be expected for a full year.  The unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission.  Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States ("GAAP") have been condensed or omitted pursuant to those rules and regulations, although we believe that the disclosures are adequate for the information not to be misleading.
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, the reported amounts of revenues and expenses during the reporting period and the disclosures of contingent liabilities.  Accordingly, ultimate results could differ materially from those estimates.

New_Accounting_Pronouncements

New Accounting Pronouncements	9 Months Ended
	Mar. 31, 2014
New Accounting Pronouncements [Abstract]	'
New Accounting Pronouncements	'
		2	New Accounting Pronouncements
	From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (the "FASB") or other standards setting bodies that are adopted by us as of the specified effective dates. Unless otherwise discussed, we believe the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial position, results of operations and cash flows upon adoption.

Loss_per_Share

Loss per Share	9 Months Ended
	Mar. 31, 2014
Loss per Share [Abstract]	'
Loss per Share	'
		3	Loss per Share
	Basic earnings per share is calculated by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding, and does not include the impact of any potentially dilutive common stock equivalents. Common stock equivalents, including warrants and options to purchase the Company's common stock, are excluded from the calculations when their effect is antidilutive. At March 31, 2014 and 2013, the calculation of diluted weighted average shares did not include preferred stock, common stock warrants, or options that are potentially convertible into common stock as those would be antidilutive due to the Company's net loss position.
	Securities not considered in the calculation of diluted weighted average shares, but that could be dilutive in the future as of March 31, 2014 and 2013, were as follows:
			March 31,
			2014		2013
	Series B preferred stock			59,065		59,065
	Common stock warrants			646,811		1,957,033
	Common stock options			2,324,072		2,312,072
	Total potential dilutive securities			3,029,948		4,328,170

Inventory

Inventory	9 Months Ended
	Mar. 31, 2014
Inventory [Abstract]	'
Inventory	'
		4	Inventory
	Inventory consisted of the following at March 31, 2014 and June 30, 2013:
			March 31,		June 30,
			2014		2013
	Raw materials		$	165,657	$	167,671
	Work in process			181,457		195,323
	Finished goods			39,906		42,577
			$	387,020	$	405,571

ShareBased_Compensation

Share-Based Compensation	9 Months Ended
	Mar. 31, 2014
Share-Based Compensation [Abstract]	'
Share-Based Compensation	'
		5	Share-Based Compensation
	The following table presents the share-based compensation expense recognized during the three and nine months ended March 31, 2014 and 2013:
			Three months				Nine months
			ended March 31,				ended March 31,
			2014		2013		2014		2013
	Cost of product sales		$	4,500	$	10,164	$	13,421	$	30,492
	Research and development expenses			3,482		7,607		10,447		25,042
	Sales and marketing expenses			879		1,386		2,636		4,568
	General and administrative expenses			4,572		8,423		38,713		25,267
	Total share-based compensation		$	13,433	$	27,580	$	65,217	$	85,369
	As of March 31, 2014, total unrecognized compensation expense related to stock-based options was $29,192 and the related weighted-average period over which it is expected to be recognized is approximately 0.87 years.
	The Company currently provides stock-based compensation under four equity incentive plans approved by the Board of Directors. Options granted under each of the plans have a ten year maximum term, an exercise price equal to at least the fair market value of the Company's common stock on the date of the grant, and varying vesting periods as determined by the Board. For stock options with graded vesting terms, the Company recognizes compensation cost on a straight-line basis over the requisite service period for the entire award.
	A summary of stock options within the Company's share-based compensation plans as of March 31, 2014 was as follows:
							Weighted
					Weighted		Average
					Average		Remaining		Aggregate
			Number of		Exercise		Contractual		Intrinsic
			Options		Price		Term		Value
	Outstanding at March 31, 2014			2,324,072	$	1.82		4.3	$	2,050,334
	Vested and expected to vest at March 31, 2014			2,238,840	$	1.86		4.23	$	1,923,611
	Vested and exercisable at March 31, 2014			2,040,732	$	1.93		3.85	$	1,714,527
	There were 26,333 options exercised during the nine months ended March 31, 2014 and 31,700 options exercised during the nine months ended March 31, 2013. The Company's current policy is to issue new shares to satisfy option exercises. The intrinsic value of the employee options exercised during the nine months ended March 31, 2014 was $15,130 and the nine months ended March 31, 2013 was $13,866.
	There were 65,000 stock option awards granted and no stock option awards granted during the nine months ended March 31, 2014 and 2013, respectively.
	Of the 65,000 options, 50,000 were director stock options issued to the Chief Executive Officer and Chairman on September 5, 2013 with an exercise price of $0.58 per share which was the closing price of the Company common stock on the day of issuance. The fair value of the stock options issued on September 5, 2013 using a Black Scholes model is $25,150 utilizing the closing price on the day of grant of $0.58 per share as the grant and exercise price, a five year term, volatility of 132.31% and a discount rate of 1.85%.
	The remaining 15,000 were employee stock options issued to three members of management on September 6, 2013 with an exercise price of $0.59 per share which was the closing price of the Company common stock on the day of issuance. The fair value of the stock options issued on September 6, 2013 using a Black Scholes model is $6,906 utilizing the closing price on the day of grant of $0.59 per share as the grant and exercise price, a five year term, volatility of 132.31% and a discount rate of 1.77%.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Mar. 31, 2014
Commitments and Contingencies [Abstract]	'
Commitments and Contingencies	'
		6	Commitments and Contingencies
	Patent and Know-How Royalty License Agreement
	The Company is the holder of an exclusive license to use certain "know-how" developed by one of the founders of a predecessor to the Company and licensed to the Company by the Lawrence Family Trust, a Company shareholder. The terms of this license agreement require the payment of a royalty based on the Net Factory Sales Price, as defined in the agreement, of licensed product sales. Because the licensor's patent application was ultimately abandoned, only a 1% "know-how" royalty based on Net Factory Sales Price, as defined in the agreement, remains applicable. To date, management believes that there have been no product sales incorporating the "know-how" and therefore no royalty is due pursuant to the terms of the agreement. Management believes that ultimately no royalties should be paid under this agreement as there is no intent to use this "know-how" in the future.
	The licensor of the "know-how" has disputed management's contention that it is not using this "know-how". On September 25, 2007 and again on October 31, 2007, the Company participated in nonbinding mediation regarding this matter; however, no settlement was reached with the Lawrence Family Trust. After additional settlement discussions, which ended in April 2008, the parties failed to reach a settlement. The parties may demand binding arbitration at any time.

Fair_Value_Measurements

Fair Value Measurements	9 Months Ended
	Mar. 31, 2014
Fair Value Measurements [Abstract]	'
Fair Value Measurements	'
		7	Fair Value Measurements
	The table below sets forth the Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of March 31, 2014 and June 30, 2013, respectively, and the fair value calculation input hierarchy level the Company has determined applies to each asset and liability category.
	Description		Balance at		Balance at		Input
			31-Mar-14		30-Jun-13		Hierarchy Level
	Assets:
	Cash and cash equivalents		$	23,702,901	$	2,899,927	Level 1
	Restricted cash			181,194		181,149	Level 1
	Liabilities:
	Warrant liability		$	678,000	$	104,000	Level 2

Preferred_Dividends

Preferred Dividends	9 Months Ended
	Mar. 31, 2014
Preferred Dividends [Abstract]	'
Preferred Dividends	'
		8	Preferred Dividends
	On December 19, 2013, the Board of Directors declared a dividend on the Series B Preferred Stock of all currently payable and accrued outstanding and cumulative dividends through December 31, 2013 in the amount of $10,632. Dividends on the Series B Preferred Stock were last paid on December 31, 2012 as declared by the Board of Directors on December 21, 2012 in the amount of $10,632. The dividends outstanding and cumulative through December 31, 2013 of $10,632 and through December 31, 2012 of $10,632 were paid as of those dates.

Shareholders_Equity

Shareholders' Equity	9 Months Ended
	Mar. 31, 2014
Shareholders' Equity [Abstract]	'
Shareholders' Equity	'
		9	Shareholders' Equity
	Common and preferred stock transactions
	Series D
	On August 29, 2013, the Company entered into an agreement to sell 3,800,985 common units, each consisting of 1 share of common stock and a warrant to purchase 0.816 shares of common stock (the "Common Units"), and 1,670 preferred units, each consisting of 1 share of Series D Convertible Preferred Stock and a warrant to purchase 1,525.23 shares of common stock (the "Preferred Units") on a firm commitment underwritten basis. The Common Units were sold at an initial per unit purchase price of $0.535 and the Preferred Units were sold at an initial per unit purchase price of $1,000. The warrants were all exercisable at $0.72 per share and had a twenty-four month term. Each share of the Series D Convertible Preferred Stock was convertible into 1,869.15 shares of common stock at any time at the option of the holder, subject to adjustment and certain ownership percentage restrictions. The preferred shares which were convertible into shares of common stock contained a beneficial conversion feature of $726,378 which was recognized as a deemed dividend to the Series D preferred shareholders on the date of issuance. This public offering resulted in gross proceeds of $3.7 million. The offering yielded approximately $3,279,292 in cash after expenses.
	Gross proceeds from public offering		$	3,703,527
	Underwriting discount			(185,176	)
	Legal and accounting expense			(184,514	)
	Listing expense			(48,500	)
	Other expense			(6,045	)
	Net proceeds			3,279,292
	During January 2014, the holder of the 1,670 shares of Series D convertible preferred stock fully exercised its right to convert the 1,670 shares of Series D convertible preferred stock into 3,121,480 shares of common stock which at the time of conversion resulted in an increase in shares of common stock outstanding from 38,419,502 to 41,540,982. Subsequent to the conversion, no shares of Series D convertible preferred stock remain outstanding.
	Common Stock
	On March 21, 2014, the Company entered into a Securities Purchase Agreement with certain investors providing for the sale of a total of 5,644,300 shares of common stock for an aggregate purchase price of $14,675,180 at a price per share of $2.60 (the "Registered Direct Offering"). The Company received net proceeds from the offering of approximately $13,818,927 from the Registered Direct Offering which will be used to meet the Company's working capital needs and general corporate purposes.
	Gross proceeds from registered direct offering		$	14,675,180
	Placement agent fees			(733,759	)
	Legal and accounting expense			(72,494	)
	Listing expense			(45,000	)
	Other expense			(5,000	)
	Net proceeds			13,818,927
	Warrant exercises
	During the month of March 2014, the holder of the Series D warrants issued in November 2010 exercised its right to purchase 1,050,000 shares of common stock. Each warrant had an exercise price of $1.56 per share of Company common stock and the exercise contributed $1,638,000 in total additional cash and equity.
	During the month of March 2014, certain holders of the warrants to purchase Company common stock issued in the October and December 2011 equity transaction exercised their right to purchase 37,574 shares of common stock. Each warrant had an original exercise price of $1.053 that was reduced in accordance with the terms of the warrant for dilution as the result of subsequent offerings to a revised exercise price of $0.944 per share of Company common stock. This created a liability of $35,470 as the stock had not been issued by the transfer agent as of the end of March, however, shares of common stock were issued during April in compliance with the contractual terms of the warrant.
	During the month of March 2014, certain holders of the warrants to purchase Company common stock issued in the October and December 2011 equity transaction exercised their right to purchase 271,091 shares of common stock. Each warrant had an original exercise price of $1.053 that was reduced in accordance with the terms of the warrant for dilution as the result of subsequent offerings to a current exercise price of $0.944 per share of Company common stock and the exercise contributed $255,910 in total additional cash and equity.
	During the month of March 2014, the holders of the warrants to purchase Company common stock issued in the August 2013 equity transaction exercised their right to purchase 5,648,738 shares of common stock. Each warrant had an exercise price of $0.72 per share of Company common stock and the exercise contributed $4,067,091 in total additional cash and equity.
	The gross proceeds from the exercise of the common stock warrants exercised were $5,961,001 during the nine months ended March 31, 2014, net of the $35,470 liability for the shares of common stock which were not issued until April 2014.
	Warrant liability and related offering cost deferral
	Based on the guidance contained in ASC 815 "Derivatives and Hedging", management has concluded that the warrants issued in the October and December 2011 underwritten registered offering of 2,500,000 shares of common stock should be classified as a derivative liability and has recorded a liability at fair value. The Company determined the fair value of the warrants using the Black-Scholes fair value model. The Company determined the fair value of the warrants on the date of the offering to be as disclosed in the tables below. The Company has recognized a change in fair value as described in the tables below:
	Change in fair value of the derivative warrant liability for the three months ended March 31, 2014 and 2013, respectively.
			Three months ended			Three months ended
			31-Mar-14			31-Mar-13
	Change in fair value of the derivative warrant liability		$	1,095,000		$	(109,000	)
	Change in fair value of the derivative warrant liability for purchaser warrants and underwriter warrants contained in an equity transaction on October 19, 2011.
			Three months ended						Three months ended
			31-Mar-14						31-Mar-13
			Quantity1			Amount			Quantity1		Amount
	Balance, beginning of the period			650,003		$	20,000			650,003	$	218,000
	Change in fair value			650,003			1,004,000					(99,000	)
	Warrants corrected			10,869			-			-		-
	Warrants exercised			(258,943	)		(423,000	)		-		-
	Balance, end of the period			401,929		$	601,000			650,003	$	119,000
	Change in fair value of the derivative warrant liability for purchaser warrants and underwriter warrants contained in an equity transaction on December 7, 2011.
			Three months ended						Three months ended
			31-Mar-14						March 31, 2013
			Quantity1			Amount			Quantity1		Amount
	Balance, beginning of the period			63,598		$	3,000			63,598	$	22,000
	Change in fair value			63,598			91,000			63,598		(10,000	)
	Warrants corrected			(400	)		-			-		-
	Warrants exercised			(12,148	)		(17,000	)		-		-
	Balance, end of the period			51,050		$	77,000			63,598	$	12,000
	Total fair value of warrant derivative liability at March 31, 2014 and 2013					$	678,000				$	131,000
	Change in fair value of the derivative warrant liability for the nine months ended March 31, 2014 and 2013, respectively.
			Nine months ended			Nine months ended
			31-Mar-14			31-Mar-13
	Change in fair value		$	1,014,000		$	(183,000	)
	Change in fair value of the derivative warrant liability for purchaser warrants and underwriter warrants contained in an equity transaction on October 19, 2011.
			Nine months ended						Nine months ended
			31-Mar-14						31-Mar-13
			Quantity1			Amount			Quantity1		Amount
	Balance, beginning of the period			650,003		$	94,000			650,003	$	286,000
	Change in fair value			650,003			914,000			650,003		(167,000	)
	Warrants corrected			10,869			16,000
	Warrants exercised			(258,943	)		(423,000	)		-		-
	Balance, end of the period			401,929		$	601,000			650,003	$	119,000
Change in fair value of the derivative warrant liability for purchaser warrants and underwriter warrants contained in an equity transaction on December 7, 2011.
		Nine months ended						Nine months ended
		31-Mar-14						31-Mar-13
		Quantity1			Amount			Quantity1		Amount
Balance, beginning of the period			63,598		$	10,000			63,598	$	28,000
Change in fair value			63,598			85,000			63,598		(16,000	)
Warrants corrected			(400	)		(1,000	)
Warrants exercised			(12,148	)		(17,000	)		-		-
Balance, end of the period			51,050		$	77,000			63,598	$	12,000
Total fair value of warrant derivative liability at March 31, 2014 and 2013					$	678,000				$	131,000
1 Quantity of warrants either issued or outstanding as of the date of valuation.
Warrants
The following table summarizes the warrants outstanding as of the beginning of the fiscal year, warrants exercised and warrants issued during the year and weighted average prices for each category.
					Weighted average
		Warrants			exercise price
Outstanding as of June 30, 2013			1,957,033		$	1.38
Warrants issued			5,648,738			0.72
Warrants corrected			10,869			0.94
Warrants exercised			(6,969,829	)		0.86
Outstanding as of March 31, 2014			646,811		$	1.14
Warrants outstanding as of March 31, 2014
Quantity				Expiration date		Exercise price
	6,000			8-Jun-15		$	1.18
	25,000			27-Jul-15			2
	157,832			21-Nov-15			1.56
	401,929			19-Oct-16			0.944
	51,050			7-Dec-16			0.944
	5,000			27-Jun-17			0.98
	646,811					$	1.14

Related_Party_Transaction

Related Party Transaction	9 Months Ended
	Mar. 31, 2014
Related Party Transaction [Abstract]	'
Related Party Transaction	'
		10	Related Party Transaction
	During the nine months ended March 31, 2014 and 2013, the Company continued to engage the services of APEX Data Systems, Inc., owned by Dwight Babcock, the Company's Chairman and Chief Executive Officer, to modify and maintain the Company's web interfaced data collection application to aggregate patient data in a controlled environment. The Audit Committee and Board of Directors approved the use of the ongoing services of APEX Data Systems. Mr. Babcock recused himself from the Board vote due to his conflict of interest. The cost recorded during nine months ended March 31, 2014 and 2013 from APEX Data Systems, Inc. for the maintenance of the web interfaced data collection application was $12,720 and $10,960. An additional $9,000 was spent on the implementation of Customer Relationship Management software in the nine months ended March 31, 2014.

Loss_per_Share_Tables

Loss per Share (Tables)	9 Months Ended
	Mar. 31, 2014
Loss per Share [Abstract]	'
Schedule of Antidilutive Securities Excluded from Computation of Loss per Share	'
	Securities not considered in the calculation of diluted weighted average shares, but that could be dilutive in the future as of March 31, 2014 and 2013, were as follows:
		March 31,
		2014		2013
	Series B preferred stock		59,065		59,065
	Common stock warrants		646,811		1,957,033
	Common stock options		2,324,072		2,312,072
	Total potential dilutive securities		3,029,948		4,328,170

Inventory_Tables

Inventory (Tables)	9 Months Ended
	Mar. 31, 2014
Inventory [Abstract]	'
Schedule of Components of Inventory	'
	Inventory consisted of the following at March 31, 2014 and June 30, 2013:
		March 31,		June 30,
		2014		2013
	Raw materials	$	165,657	$	167,671
	Work in process		181,457		195,323
	Finished goods		39,906		42,577
		$	387,020	$	405,571

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	9 Months Ended
	Mar. 31, 2014
Share-Based Compensation [Abstract]	'
Schedule of Share-Based Compensation Expense	'
	The following table presents the share-based compensation expense recognized during the three and nine months ended March 31, 2014 and 2013:
		Three months				Nine months
		ended March 31,				ended March 31,
		2014		2013		2014		2013
	Cost of product sales	$	4,500	$	10,164	$	13,421	$	30,492
	Research and development expenses		3,482		7,607		10,447		25,042
	Sales and marketing expenses		879		1,386		2,636		4,568
	General and administrative expenses		4,572		8,423		38,713		25,267
	Total share-based compensation	$	13,433	$	27,580	$	65,217	$	85,369
Schedule of Stock Option within Share-based Compensation Plans	'
	A summary of stock options within the Company's share-based compensation plans as of March 31, 2014 was as follows:
						Weighted
				Weighted		Average
				Average		Remaining		Aggregate
		Number of		Exercise		Contractual		Intrinsic
		Options		Price		Term		Value
	Outstanding at March 31, 2014		2,324,072	$	1.82		4.3	$	2,050,334
	Vested and expected to vest at March 31, 2014		2,238,840	$	1.86		4.23	$	1,923,611
	Vested and exercisable at March 31, 2014		2,040,732	$	1.93		3.85	$	1,714,527

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	9 Months Ended
	Mar. 31, 2014
Fair Value Measurements [Abstract]	'
Schedule of Financial Assets and Liabilities Accounted for at Fair Value on Recurring Basis and Fair Value Calculation Input Hierarchy Level	'
	The table below sets forth the Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of March 31, 2014 and June 30, 2013, respectively, and the fair value calculation input hierarchy level the Company has determined applies to each asset and liability category.
	Description	Balance at		Balance at		Input
		31-Mar-14		30-Jun-13		Hierarchy Level
	Assets:
	Cash and cash equivalents	$	23,702,901	$	2,899,927	Level 1
	Restricted cash		181,194		181,149	Level 1
	Liabilities:
	Warrant liability	$	678,000	$	104,000	Level 2

Shareholders_Equity_Tables

Shareholders' Equity (Tables)	9 Months Ended
	Mar. 31, 2014
Shareholders' Equity [Abstract]	'
Schedule of Proceeds from Common Stock Offering	'
	This public offering resulted in gross proceeds of $3.7 million. The offering yielded approximately $3,279,292 in cash after expenses.
	Gross proceeds from public offering		$	3,703,527
	Underwriting discount			(185,176	)
	Legal and accounting expense			(184,514	)
	Listing expense			(48,500	)
	Other expense			(6,045	)
	Net proceeds			3,279,292
	On March 21, 2014, the Company entered into a Securities Purchase Agreement with certain investors providing for the sale of a total of 5,644,300 shares of common stock for an aggregate purchase price of $14,675,180 at a price per share of $2.60 (the "Registered Direct Offering"). The Company received net proceeds from the offering of approximately $13,818,927 from the Registered Direct Offering which will be used to meet the Company's working capital needs and general corporate purposes.
	Gross proceeds from registered direct offering		$	14,675,180
	Placement agent fees			(733,759	)
	Legal and accounting expense			(72,494	)
	Listing expense			(45,000	)
	Other expense			(5,000	)
	Net proceeds			13,818,927
Schedule of Fair Value of Warrants	'
	Change in fair value of the derivative warrant liability for the three months ended March 31, 2014 and 2013, respectively.
			Three months ended			Three months ended
			31-Mar-14			31-Mar-13
	Change in fair value of the derivative warrant liability		$	1,095,000		$	(109,000	)
	Change in fair value of the derivative warrant liability for purchaser warrants and underwriter warrants contained in an equity transaction on October 19, 2011.
			Three months ended						Three months ended
			31-Mar-14						31-Mar-13
			Quantity1			Amount			Quantity1		Amount
	Balance, beginning of the period			650,003		$	20,000			650,003	$	218,000
	Change in fair value			650,003			1,004,000					(99,000	)
	Warrants corrected			10,869			-			-		-
	Warrants exercised			(258,943	)		(423,000	)		-		-
	Balance, end of the period			401,929		$	601,000			650,003	$	119,000
	Change in fair value of the derivative warrant liability for purchaser warrants and underwriter warrants contained in an equity transaction on December 7, 2011.
			Three months ended						Three months ended
			31-Mar-14						March 31, 2013
			Quantity1			Amount			Quantity1		Amount
	Balance, beginning of the period			63,598		$	3,000			63,598	$	22,000
	Change in fair value			63,598			91,000			63,598		(10,000	)
	Warrants corrected			(400	)		-			-		-
	Warrants exercised			(12,148	)		(17,000	)		-		-
	Balance, end of the period			51,050		$	77,000			63,598	$	12,000
	Total fair value of warrant derivative liability at March 31, 2014 and 2013					$	678,000				$	131,000
	Change in fair value of the derivative warrant liability for the nine months ended March 31, 2014 and 2013, respectively.
			Nine months ended			Nine months ended
			31-Mar-14			31-Mar-13
	Change in fair value		$	1,014,000		$	(183,000	)
	Change in fair value of the derivative warrant liability for purchaser warrants and underwriter warrants contained in an equity transaction on October 19, 2011.
			Nine months ended						Nine months ended
			31-Mar-14						31-Mar-13
			Quantity1			Amount			Quantity1		Amount
	Balance, beginning of the period			650,003		$	94,000			650,003	$	286,000
	Change in fair value			650,003			914,000			650,003		(167,000	)
	Warrants corrected			10,869			16,000
	Warrants exercised			(258,943	)		(423,000	)		-		-
	Balance, end of the period			401,929		$	601,000			650,003	$	119,000
	Change in fair value of the derivative warrant liability for purchaser warrants and underwriter warrants contained in an equity transaction on December 7, 2011.
			Nine months ended						Nine months ended
			31-Mar-14						31-Mar-13
			Quantity1			Amount			Quantity1		Amount
	Balance, beginning of the period			63,598		$	10,000			63,598	$	28,000
	Change in fair value			63,598			85,000			63,598		(16,000	)
	Warrants corrected			(400	)		(1,000	)
	Warrants exercised			(12,148	)		(17,000	)		-		-
	Balance, end of the period			51,050		$	77,000			63,598	$	12,000
	Total fair value of warrant derivative liability at March 31, 2014 and 2013					$	678,000				$	131,000
	1 Quantity of warrants either issued or outstanding as of the date of valuation.
Schedule of Warrants Activity	'
	The following table summarizes the warrants outstanding as of the beginning of the fiscal year, warrants exercised and warrants issued during the year and weighted average prices for each category.
						Weighted average
			Warrants			exercise price
	Outstanding as of June 30, 2013			1,957,033		$	1.38
	Warrants issued			5,648,738			0.72
	Warrants corrected			10,869			0.94
	Warrants exercised			(6,969,829	)		0.86
	Outstanding as of March 31, 2014			646,811		$	1.14
	Warrants outstanding as of March 31, 2014
	Quantity				Expiration date		Exercise price
		6,000			8-Jun-15		$	1.18
		25,000			27-Jul-15			2
		157,832			21-Nov-15			1.56
		401,929			19-Oct-16			0.944
		51,050			7-Dec-16			0.944
		5,000			27-Jun-17			0.98
		646,811					$	1.14

Loss_per_Share_Details

Loss per Share (Details)	9 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities excluded from computation of earnings per share, amount	3,029,948	4,328,170
Series B Preferred Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities excluded from computation of earnings per share, amount	59,065	59,065
Warrant [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities excluded from computation of earnings per share, amount	646,811	1,957,033
Employee Stock Option [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities excluded from computation of earnings per share, amount	2,324,072	2,312,072

Inventory_Details

Inventory (Details) (USD $)	Mar. 31, 2014	Jun. 30, 2013
Inventory [Abstract]	'	'
Raw materials	$165,657	$167,671
Work in process	181,457	195,323
Finished goods	39,906	42,577
Total inventory	$387,020	$405,571

ShareBased_Compensation_Schedu

Share-Based Compensation (Schedule of Share-Based Compensation Expense) (Details) (USD $)	3 Months Ended		9 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Share-based compensation	$13,433	$27,580	$65,217	$85,369
Unrecognized compensation expense related to stock-based options and awards	29,192	'	29,192	'
Unrecognized compensation expense related to stock-based options and awards, weighted-average recognition period	'	'	'10 months 13 days	'
Stock options, maximum term	'	'	'10 years	'
Cost of Product Sales [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Share-based compensation	4,500	10,164	13,421	30,492
Research and Development Expenses [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Share-based compensation	3,482	7,607	10,447	25,042
Sales and Marketing Expenses [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Share-based compensation	879	1,386	2,636	4,568
General and Administration Expenses [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Share-based compensation	$4,572	$8,423	$38,713	$25,267

ShareBased_Compensation_Schedu1

Share-Based Compensation (Schedule of Stock Option Activity) (Details) (USD $)	0 Months Ended		9 Months Ended
	Sep. 05, 2013	Sep. 06, 2013	Mar. 31, 2014	Mar. 31, 2013
Number of Options	'	'	'	'
Outstanding at March 31, 2014	'	'	2,324,072	'
Vested and expected to vest at March 31, 2014	'	'	2,238,840	'
Vested and exercisable at March 31, 2014	'	'	2,040,732	'
Weighted Average Exercise Price	'	'	'	'
Outstanding at March 31, 2014	'	'	$1.82	'
Vested and expected to vest at March 31, 2014	'	'	$1.86	'
Vested and exercisable at March 31, 2014	'	'	$1.93	'
Weighted Average Remaining Contractual Term	'	'	'	'
Outstanding at March 31, 2014	'	'	'4 years 3 months 18 days	'
Vested and expected to vest at March 31, 2014	'	'	'4 years 2 months 23 days	'
Vested and exercisable at March 31, 2014	'	'	'3 years 10 months 6 days	'
Average Intrinsic Value	'	'	'	'
Outstanding at March 31, 2014	'	'	$2,050,334	'
Vested and expected to vest at March 31, 2014	'	'	1,923,611	'
Vested and exercisable at March 31, 2014	'	'	1,714,527	'
Options exercised	'	'	26,333	31,700
Aggregate intrinsic value of option exercised	'	'	15,130	13,866
Stock options granted	50,000	15,000	65,000	'
Stock options issued, exercise price	$0.58	$0.59	'	'
Fair value of stock options granted	$25,150	$6,906	'	'
Exercise price	$0.58	$0.59	'	'
Expected term	'5 years	'5 years	'	'
Volatility	132.31%	132.31%	'	'
Discount rate	1.85%	1.77%	'	'

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (Patent Rights Know-how and License Agreements [Member])	Mar. 31, 2014
Patent Rights Know-how and License Agreements [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Percentage of royalty payment on net sales	1.00%

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (Fair Value, Measurements, Recurring [Member], USD $)	Mar. 31, 2014	Jun. 30, 2013
Level 1 [Member]	'	'
Assets:	'	'
Cash and cash equivalents	$23,702,901	$2,899,927
Restricted cash	181,194	181,149
Level 2 [Member]	'	'
Liabilities:	'	'
Warrant liability	$678,000	$104,000

Preferred_Dividends_Details

Preferred Dividends (Details) (USD $)	9 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Dividends Payable [Line Items]	'	'
Preferred dividends paid	$10,632	$10,632

Shareholders_Equity_Common_and

Shareholders' Equity (Common and Preferred Stock Transactions) (Details) (USD $)

0 Months Ended

3 Months Ended

9 Months Ended

0 Months Ended

1 Months Ended

3 Months Ended

0 Months Ended

1 Months Ended

Mar. 21, 2014

Aug. 29, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Jan. 31, 2014

Dec. 31, 2013

Jun. 30, 2013

Aug. 29, 2013

Aug. 29, 2013

Mar. 21, 2014

Aug. 29, 2013

Jan. 31, 2014

Dec. 31, 2011

Aug. 29, 2013

Jan. 31, 2014

Common Unit Warrants [Member]

Preferred Unit Warrants [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Series D Preferred Stock [Member]

Series D Preferred Stock [Member]

Class of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sale of common stock

'

'

'

'

'

'

'

'

'

'

'

5,644,300

3,800,985

'

2,500,000

1,670

'

Number of shares covered by each warrant

'

'

'

'

'

'

'

'

'

0.816

'

'

'

'

'

'

'

Number of shares number of shares covered by warrant

'

'

'

'

'

'

'

'

'

'

1,525.23

'

'

'

'

'

'

Stock issued, price per share

'

'

'

'

'

'

'

'

'

'

'

$2.60

$0.54

'

'

$1,000

'

Exercise price

'

'

1.14

'

1.14

'

'

'

1.38

0.72

0.72

'

'

'

'

'

'

Warrant term

'

'

'

'

'

'

'

'

'

'24 months

'24 months

'

'

'

'

'

'

Number of common shares issuable upon conversion

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,869.15

'

Beneficial conversion feature

'

'

'

'

$726,378

'

'

'

'

'

'

'

'

'

'

'

'

Gross proceeds from public offering

14,675,180

3,703,527

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Underwriting discount

'

-185,176

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Placement agent fees

-733,759

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Legal and accounting expense

-72,494

-184,514

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Listing expense

-45,000

-48,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other expense

-5,000

-6,045

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net proceeds

$13,818,927

$3,279,292

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares converted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,670

Number of common shares issued upon conversion

'

'

'

'

'

'

'

'

'

'

'

'

'

3,121,480

'

'

'

Common stock, shares outstanding

'

'

54,181,444

'

54,181,444

'

41,540,982

38,419,502

34,618,517

'

'

'

'

'

'

'

'

Shareholders_Equity_Warrant_Ex

Shareholders' Equity (Warrant Exercises) (Details) (USD $)	9 Months Ended			1 Months Ended			1 Months Ended		1 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Jun. 30, 2013	Mar. 31, 2014	Mar. 31, 2014	Dec. 31, 2011	Mar. 31, 2014	Dec. 31, 2011	Mar. 31, 2014
				Warrants Issued in November 2010 [Member]	Warrants Issued in 2011 [Member]	Warrants Issued in 2011 [Member]	Warrants Issued in 2011, Two [Member]	Warrants Issued in 2011, Two [Member]	Warrants Issued in 2013 [Member]
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'	'	'
Warrants exercised	6,969,829	'	'	1,050,000	37,574	'	271,091	'	5,648,738
Exercise price	$0.86	'	'	$1.56	$0.94	'	$0.94	'	$0.72
Warrants issued, exercise price	1.14	'	1.38	'	'	1.053	'	1.053	'
Proceeds from exercise of warrants	$5,961,001	$1,825	'	$1,638,000	$35,470	'	$255,910	'	$4,067,091
Liability for shares of common stock	$35,470	'	'	'	'	'	'	'	'

Shareholders_Equity_Schedule_o

Shareholders' Equity (Schedule of Inputs for Fair Value Model) (Details) (USD $)	3 Months Ended				9 Months Ended
	Mar. 31, 2014		Mar. 31, 2013		Mar. 31, 2014		Mar. 31, 2013
Class of Warrant or Right [Line Items]	'		'		'		'
Balance, beginning of period	'		'		1,957,033		'
Warrants corrected	'		'		10,869		'
Warrants exercised	'		'		-6,969,829		'
Balance, end of period	646,811		'		646,811		'
Value of warrants issued:	'		'		'		'
Change in fair value of warrant derivative liability	$1,095,000		($109,000)		$1,014,000		($183,000)
Balance, end of period	678,000		131,000		678,000		131,000
Common Stock Purchaser Warrants [Member]	'		'		'		'
Class of Warrant or Right [Line Items]	'		'		'		'
Balance, beginning of period	650,003	[1]	650,003	[1]	650,003	[1]	650,003	[1]
Warrants corrected	10,869	[1]	'	[1]	10,869	[1]	'	[1]
Warrants exercised	-258,943	[1]	'	[1]	-258,943	[1]	'	[1]
Balance, end of period	401,929	[1]	650,003	[1]	401,929	[1]	650,003	[1]
Value of warrants issued:	'		'		'		'
Balance, beginning of period	20,000		218,000		94,000		286,000
Change in fair value of warrant derivative liability	1,004,000		-99,000		914,000		-167,000
Warrants corrected	'		'		16,000		'
Warrants exercised	-423,000		'		-423,000		'
Balance, end of period	601,000		119,000		601,000		119,000
Over Allotment Warrants [Member]	'		'		'		'
Class of Warrant or Right [Line Items]	'		'		'		'
Balance, beginning of period	63,598	[1]	63,598	[1]	63,598	[1]	63,598	[1]
Warrants corrected	-400	[1]	'	[1]	-400	[1]	'	[1]
Warrants exercised	-12,148	[1]	'	[1]	-12,148	[1]	'	[1]
Balance, end of period	51,050	[1]	63,598	[1]	51,050	[1]	63,598	[1]
Value of warrants issued:	'		'		'		'
Balance, beginning of period	3,000		22,000		10,000		28,000
Change in fair value of warrant derivative liability	91,000		-10,000		85,000		-16,000
Warrants corrected	'		'		-1,000		'
Warrants exercised	-17,000		'		-17,000		'
Balance, end of period	$77,000		$12,000		$77,000		$12,000
[1]	Quantity of warrants either issued or outstanding as of the date of valuation.

Shareholders_Equity_Warrants_D

Shareholders' Equity (Warrants) (Details) (USD $)	9 Months Ended
	Mar. 31, 2014
Warrants	'
Balance, beginning of period	1,957,033
Warrants issued	5,648,738
Warrants corrected	10,869
Warrants exercised	-6,969,829
Balance, end of period	646,811
Weighted average exercise price	'
Beginning balance outstanding	1.38
Warrants issued	0.72
Warrants corrected	$0.94
Warrants exercised	$0.86
Ending balance outstanding	1.14

Shareholders_Equity_Additional

Shareholders' Equity (Additional Information about Warrants) (Details)	Mar. 31, 2014	Jun. 30, 2013	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014
			Range of Exercise Price One [Member]	Range of Exercise Price Two [Member]	Range of Exercise Price Four [Member]	Range of Exercise Price Five [Member]	Range of Exercise Price Six [Member]	Range of Exercise Price Seven [Member]
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'	'
Quantity	646,811	1,957,033	6,000	25,000	157,832	401,929	51,050	5,000
Expiration date	'	'	8-Jun-15	27-Jul-15	21-Nov-15	19-Oct-16	7-Dec-16	27-Jun-17
Exercise price	1.14	1.38	1.18	2	1.56	0.944	0.944	0.98

Related_Party_Transaction_Deta

Related Party Transaction (Details) (Affiliated Entity [Member], USD $)	9 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Affiliated Entity [Member]	'	'
Related Party Transaction [Line Items]	'	'
Maintenance costs	$12,720	$10,960
Software implementation costs	$9,000	'